[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Lee KH, Joo JK, Kim DY, Lee JS, Choi C, Lee JH: Mesenteric extraskeletal osteosarcoma with telangiectatic features: a case report. BMC Cancer; 2007;7:82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Extraskeletal osteosarcoma is a rare malignant mesenchymal tumor, with a predominant occurrence in the extremities.
  • Computed tomography showed a 15 x 9.7 cm heterogeneously enhancing mass, with mottled calcification and a cystic portion, occupying the left upper quadrant of the abdominal cavity.
  • Curative resection of the tumor was performed, and the excised tumor was composed of large multilocular cysts containing old hematomas and necrotic debris.
  • Despite postoperative chemotherapy, he developed a recurrent peritoneal mass and multiple lung metastases 3 months postoperatively.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Mesentery / pathology. Osteosarcoma / diagnosis. Telangiectasis / diagnosis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):119-22 [16330951.001]
  • [Cites] Histopathology. 2006 Jan;48(1):3-12 [16359532.001]
  • [Cites] Cancer. 1971 May;27(5):1121-33 [5281245.001]
  • [Cites] Cancer. 1976 Dec;38(6):2538-47 [1069603.001]
  • [Cites] Cancer. 1983 Feb 15;51(4):727-34 [6571801.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1132-42 [3475157.001]
  • [Cites] Skeletal Radiol. 2005 Oct;34(10):649-52 [15834564.001]
  • [Cites] Hum Pathol. 1991 Jun;22(6):583-90 [1864588.001]
  • [Cites] Cancer. 1993 May 15;71(10):3014-9 [8490830.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2253-9 [8635029.001]
  • [Cites] Radiographics. 1997 Sep-Oct;17(5):1205-31 [9308111.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):588-94 [9591729.001]
  • [Cites] Cancer. 1956 Sep-Oct;9(5):1027-43 [13364888.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2762-70 [2160317.001]
  • (PMID = 17504524.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1878495
  •  go-up   go-down


2. De Padua M, Bhandari TP, Pingle J: Primary osteoliposarcoma of the bone. Indian J Pathol Microbiol; 2009 Jan-Mar;52(1):80-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some of the reports have referred to these tumors as malignant mesenchymoma.
  • Radiologically, a tumor in the lower end of the right femur was seen extending into the soft tissue.
  • The patient received three cycles of neo-adjuvant chemotherapy followed by limb-salvage surgery with provisions for a custom-made prosthesis.
  • The final diagnosis was osteoliposarcoma.
  • Only 21% tumor necrosis (effects of chemotherapy) was observed.
  • Presently, 26 months following diagnosis, the patient is fine with no evidence of local recurrence or distant metastasis.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / pathology. Liposarcoma / diagnosis. Liposarcoma / pathology. Osteosarcoma / diagnosis. Osteosarcoma / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Biopsy. Femur / pathology. Femur / radiography. Humans. Male

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136790.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Lee JA, Kim TW, Min JH, Byon SJ, Jang SH, Choi SY, Kim HJ: [A case of undifferentiated (embryonal) liver sarcoma mimicking klatskin tumor in an adult]. Korean J Gastroenterol; 2010 Feb;55(2):144-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of undifferentiated (embryonal) liver sarcoma mimicking klatskin tumor in an adult].
  • Undifferentiated sarcoma is an uncommon primary malignant tumor of the liver typically occurring in older children.
  • It is also referred to as malignant mesenchymoma, fibromyxosarcoma, or mesenchymal sarcoma.
  • We experienced a case of undifferentiated sarcoma in 72-year-old male.
  • These tumor cells were positive for vimentin only, and the tumor was consistent with undifferentiated sarcoma of the liver.
  • [MeSH-major] Liver Neoplasms / diagnosis. Sarcoma / diagnosis
  • [MeSH-minor] Aged. Bile Ducts, Intrahepatic / pathology. Diagnosis, Differential. Dilatation, Pathologic. Humans. Klatskin Tumor / diagnosis. Male. Positron-Emission Tomography. Tomography, X-Ray Computed. Tuberculosis / diagnostic imaging. Tuberculosis / drug therapy. Ultrasonography. Vimentin / metabolism

  • Genetic Alliance. consumer health - Embryonal Sarcoma.
  • Genetic Alliance. consumer health - Klatskin tumor.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20168062.001).
  • [ISSN] 2233-6869
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Vimentin
  •  go-up   go-down


Advertisement
4. Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, Marsden HB, Martelli H, Sanchez de Toledo J, Spicer RD, Spooner D, Terrier-Lacombe MJ, van Unnik A, Oberlin O: Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol; 2005 Apr 20;23(12):2618-28
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89.
  • PURPOSE: To improve outcome for children with nonmetastatic rhabdomyosarcoma and to reduce systematic use of local therapy.
  • PATIENTS AND METHODS: Five hundred three previously untreated patients aged from birth to 18 years, recruited between 1989 and 1995, were allocated to one of six treatment schedules by site and stage.
  • Primary site, T-stage, and pathologic subtype were independent factors in predicting OS by multivariate analysis.
  • Differences between EFS and OS reflected local treatment strategy and successful re-treatment for some patients after relapse.
  • Patients with stage III disease treated with a novel six-drug combination showed improved survival compared with the Malignant Mesenchymal Tumor 84 study (MMT 84; 5-year OS, 60% v 42%, respectively).
  • OS was not significantly better than that achieved in the previous MMT 84 study, but 49% of survivors were cured without significant local therapy.
  • CONCLUSION: Selective avoidance of local therapy is justified in some patients, though further work is required to prospectively identify those for whom this is most applicable.
  • The value of the new six-drug chemotherapy combination is being evaluated further in a randomized study (MMT 95).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / pathology
  • [MeSH-minor] Adolescent. Carboplatin / administration & dosage. Child. Child, Preschool. Dactinomycin / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Epirubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Infant. Infant, Newborn. Male. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Teniposide / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Malignant mesenchymal tumor.
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Apr 20;23(12):2586-7 [15728222.001]
  • (PMID = 15728225.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 957E6438QA / Teniposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide; IVA protocol; VCE protocol
  •  go-up   go-down


5. Mrad K, Sassi S, Smida M, Oubiche F, Mekni A, Romdhane KB: Osteosarcoma with rhabdomyosarcomatous component or so-called malignant mesenchymoma of bone. Pathologica; 2004 Dec;96(6):475-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma with rhabdomyosarcomatous component or so-called malignant mesenchymoma of bone.
  • BACKGROUND: Primary malignant mesenchymoma of the bone is a rare neoplasm consisting of two or more unrelated malignant mesenchymal components.
  • OBSERVATION: We report an exceedingly rare case of primary malignant mesenchymoma of bone composed of rhabdomyosarcoma, osteosarcoma, and a minor chondrosarcoma component, arising in the right proximal humerus of a 15-year-old girl.
  • The rhabdomyosarcomatous component was present in the initial biopsy and persisted in surgical specimen following chemotherapy.
  • CONCLUSION: Effect of chemotherapy is enigmatic since rhabdomyosarcomatous component could appear, persist or disappear after chemotherapy according to literature.
  • [MeSH-major] Bone Neoplasms / pathology. Humerus / pathology. Mesenchymoma / pathology. Neoplasms, Multiple Primary / pathology. Osteosarcoma / pathology. Rhabdomyosarcoma / pathology
  • [MeSH-minor] Adolescent. Antimetabolites, Antineoplastic / therapeutic use. Chondrosarcoma / diagnosis. Chondrosarcoma / drug therapy. Chondrosarcoma / pathology. Chondrosarcoma / radiography. Chondrosarcoma / surgery. Combined Modality Therapy. Desmin / analysis. Diagnosis, Differential. Fatal Outcome. Female. Fibrosarcoma / diagnosis. Fibrosarcoma / drug therapy. Fibrosarcoma / pathology. Fibrosarcoma / radiography. Fibrosarcoma / surgery. Humans. Methotrexate / therapeutic use. Neoplasm Proteins / analysis. Osteolysis / etiology. Postoperative Complications / etiology. Pulmonary Embolism / etiology. Sarcoma, Ewing / diagnosis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for malignant mesenchymoma .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792374.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Desmin; 0 / Neoplasm Proteins; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 12
  •  go-up   go-down


6. Sari R, Altunbas H, Ozdogan M, Gurer EI, Karayalcin U: Severe and prolonged hypoglycemia triggered by long-acting octreotide in a patient with malignant mesenchymal tumor: case report. J Chemother; 2003 Feb;15(1):85-8
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe and prolonged hypoglycemia triggered by long-acting octreotide in a patient with malignant mesenchymal tumor: case report.
  • Somatostatin analogues are potent growth hormone and glucagon inhibitors and are commonly used in the treatment of several endocrine and non-endocrine disorders.
  • We report severe and longstanding hypoglycemia triggered by long-acting octreotide (Sandostatin LAR) in a 62-year-old women with malignant mesenchymal tumor.
  • Hypoglycemia developed after 6 hours of octreotide injection and she was admitted to the emergency unit with sweating, tremor, palpitation and confusion.
  • In patients prone to tumor hypoglycemia, long-acting octreotide may trigger severe and prolonged hypoglycemia due to suppression of counter-regulatory hormones; clinical trial with short-acting octreotide may be warranted to predict and prevent this life-threating complication.
  • [MeSH-minor] Female. Glucocorticoids / administration & dosage. Glucocorticoids / pharmacology. Humans. Mesoderm / pathology. Middle Aged. Neoplasms / drug therapy. Prednisolone / administration & dosage. Prednisolone / pharmacology. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant mesenchymal tumor.
  • Genetic Alliance. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Hypoglycemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12678421.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Glucocorticoids; 9PHQ9Y1OLM / Prednisolone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


7. Deslée G, Guillou PJ, Baehrel B, Lebargy F: Malignant mesenchymoma of the pleura. Interact Cardiovasc Thorac Surg; 2003 Sep;2(3):376-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesenchymoma of the pleura.
  • Malignant mesenchymomas are rare soft tissue tumors of mesenchymal origin.
  • The treatment associated surgical resection, chemotherapy and radiotherapy.
  • Sixteen months after the diagnosis a metastatic retroperitoneal sarcoma with osteosarcomatous differentiation appeared without any sign of thoracic recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17670075.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Orbach D, Rey A, Oberlin O, Sanchez de Toledo J, Terrier-Lacombe MJ, van Unnik A, Quintana E, Stevens MC: Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee. J Clin Oncol; 2005 Jul 1;23(19):4363-71
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee.
  • PURPOSE: To describe the outcome of infants with a histologically confirmed diagnosis of malignant mesenchymal tumor (MMT) included in the International Society of Paediatric Oncology studies MMT 84 and MMT 89.
  • Sixty-four patients had rhabdomyosarcoma (RMS), 26 had undifferentiated sarcoma, and 12 had other histology.
  • Clinical TNM stage was stage I (41%), II (39%), III (6%), and IV (14%).
  • First-line treatment was ifosfamide, vincristine, dactinomycin, whereas the second-line combination consisted of either cisplatin and doxorubicin (in MMT 84) or vincristine, carboplatin, etoposide/teniposide (in MMT 89).
  • Chemotherapy doses were adapted to age.
  • Local therapy was conservative surgery as often as possible.
  • Only two of 13 stage IV patients survived.
  • Infants with alveolar subtype had a poorer survival than those with non-RMS MMT or nonalveolar RMS (5-year OS, 37% v 75% or 82%, respectively; P = .002).
  • CONCLUSION: OS was satisfactory even when local treatment was not aggressive, although the prognosis was poor for infants with alveolar RMS or metastatic tumors.
  • Chemotherapy toxicity was manageable with appropriate dose modification.
  • [MeSH-major] Sarcoma / drug therapy
  • [MeSH-minor] Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Dactinomycin / therapeutic use. Doxorubicin / administration & dosage. Epirubicin / therapeutic use. Etoposide / administration & dosage. Humans. Ifosfamide / therapeutic use. Infant. Infant, Newborn. Neoplasm Metastasis. Neoplasm Recurrence, Local. Rhabdomyosarcoma / drug therapy. Survival Analysis. Teniposide / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Malignant mesenchymal tumor.
  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994146.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 957E6438QA / Teniposide; UM20QQM95Y / Ifosfamide; CEV protocol; IVA protocol
  •  go-up   go-down


9. Chow LT, Kumta SM: Primary osteochondrorhabdomyosarcoma (malignant mesenchymoma) of the fibula: a rare tumour in an unusual site -- case report and review of the literature. APMIS; 2004 Sep;112(9):617-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary osteochondrorhabdomyosarcoma (malignant mesenchymoma) of the fibula: a rare tumour in an unusual site -- case report and review of the literature.
  • Malignant mesenchymoma, defined by Stout as sarcomas comprising two or more unrelated differentiated tissue elements other than a fibrosarcoma component, is rare.
  • We report a case of primary malignant mesenchymoma of the proximal fibula in a 10-year-old female student who presented with pain and swelling of the right knee for 2 months.
  • Including our present patient, 16 cases of primary malignant mesenchymoma of bone are found in the English literature, affecting mainly adolescents and young adults, with a slight male predominance and predilection for the metaphysis of long bones, especially around the knee.
  • About 60% of the patients, all with metastasis, died mostly within one year of diagnosis.
  • The clinical features of primary malignant mesenchymoma of bone thus resemble those of conventional osteosarcoma.
  • Moreover, our case illustrates that, with combination chemotherapy targeted for individual elements, the prognosis of this rare tumour might be much improved, as in osteosarcoma.
  • [MeSH-major] Bone Neoplasms / pathology. Fibula / pathology. Mesenchymoma / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Child. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15601312.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 22
  •  go-up   go-down


10. Brichard B, De Potter P, Godfraind C, Vermylen C: Embryonal rhabdomyosarcoma presenting as conjunctival tumor. J Pediatr Hematol Oncol; 2003 Aug;25(8):651-2
Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Embryonal rhabdomyosarcoma presenting as conjunctival tumor.
  • The authors report the case of a 10-year-old girl who presented with a focal conjunctival lesion of the right eye.
  • She received chemotherapy alone according to the Malignant Mesenchymal Tumor 95 Study (stage II nonalveolar orbital tumors) and is still in complete remission 6 months after the completion of treatment.
  • The authors discuss the prognosis and differential diagnosis of these lesions.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Diagnosis, Differential. Female. Humans. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12902922.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Corapçioglu F, Sarper N, Demir H, Güvenç BH, Sözübir S, Akansel G, Berk FS: A child with undifferentiated sarcoma of the liver complicated with bronchobiliary fistula and detected by hepatobiliary scintigraphy. Pediatr Hematol Oncol; 2004 Jul-Aug;21(5):427-33
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A child with undifferentiated sarcoma of the liver complicated with bronchobiliary fistula and detected by hepatobiliary scintigraphy.
  • Undifferentiated (embryonal) sarcoma of the liver (USL) is a rare malignant mesenchymal tumor principally affecting patients of pediatric age.
  • Bronchobiliary fistula is a very rare complication in patients with liver tumor.
  • To the authors' knowledge, this is the first report of a bronchobiliary fistula resulting from tumor invasion in a child with liver sarcoma.
  • An extended right hepatectomy and total resection of the mass was performed, leaving patchy tumoral invasion of the anterior diaphragmatic surface followed by combined chemotherapy regimen.
  • Hepatobiliary scintigraphy is the useful diagnostic procedure to define bronchobiliary fistula in children with liver tumor and clinical suspicion of bronchobiliary fistula.
  • [MeSH-major] Biliary Tract Diseases / complications. Biliary Tract Diseases / radionuclide imaging. Bronchial Fistula / complications. Bronchial Fistula / radionuclide imaging. Liver Neoplasms / complications. Sarcoma / complications. Technetium Tc 99m Disofenin

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15205086.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] QTJ2VIW97T / Technetium Tc 99m Disofenin
  •  go-up   go-down


12. Liang X, Xiao-Min S, Jiang-Ping X, Jie-Yu Y, Xiao-Jun Z, Zhi-Ren F, Guo-Shan D, Rui-Dong L: Liver transplantation for primary hepatic leiomyosarcoma: a case report and review of the literatures. Med Oncol; 2010 Dec;27(4):1269-72
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary hepatic leiomyosarcoma (PHL), a malignant mesenchymal tumor of myogenic origin, is exceedingly rare.
  • Patients may be afflicted with a wide spectrum of nonspecific symptoms, and most of the laboratory data are unhelpful to diagnosis.
  • Here, we report a 44-year-old woman with anorexia and right upper quadrant pain who was diagnosed as having malignant hepatic tumor within the Milan criteria and treated by orthotopic liver transplantation (OLT), the pathologic diagnosis of PHL was made by postoperative immunohistochemical study.
  • She underwent six courses of intravenous chemotherapy and enjoyed a 14-month tumor recurrence-free survival until the lymph node metastasis was detected, then we switched the tacrolimus to sirolimus and the patient survived for 20 months additionally.
  • The diagnostic and therapeutic features of PHL are also discussed by reviewing the literatures.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunosuppressive Agents / therapeutic use. Leiomyosarcoma / therapy. Liver Transplantation
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Humans. Lymphatic Metastasis. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1995 Jan 5;332(1):19-25 [7990861.001]
  • [Cites] Eur Radiol. 2008 Oct;18(10 ):2196-205 [18463872.001]
  • [Cites] Surg Today. 1999;29(1):67-70 [9934835.001]
  • [Cites] Nat Med. 2002 Feb;8(2):128-35 [11821896.001]
  • [Cites] Am J Transplant. 2006 Feb;6(2):392-7 [16426326.001]
  • [Cites] Gastroenterol Clin Biol. 1993;17(3):218-22 [8330697.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Apr;12(2):485-97 [12916465.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1391-6 [17315167.001]
  • [Cites] Dig Dis Sci. 2003 Apr;48(4):677-82 [12741455.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):817-26 [17527068.001]
  • [Cites] Ital J Gastroenterol. 1996 Feb-Mar;28(2):98-101 [8782003.001]
  • [Cites] J Submicrosc Cytol Pathol. 1991 Oct;23(4):643-7 [1764691.001]
  • [Cites] N Engl J Med. 1995 Jan 5;332(1):12-8 [7990860.001]
  • [Cites] World J Surg. 2009 Nov;33(11):2420-6 [19693632.001]
  • [Cites] Pediatr Transplant. 2001 Oct;5(5):365-9 [11560757.001]
  • [Cites] Eur J Radiol. 1995 Mar;19(3):177-82 [7601167.001]
  • (PMID = 19997990.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


13. Gerressen M, Donner A, Jundt G, Jänicke S, Smeets R, Riediger D, Ghassemi A: [High-grade osteosarcoma of the maxillary sinus. A case report]. Mund Kiefer Gesichtschir; 2006 Sep;10(5):347-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Osteosarcoma of the jaw (JOS) constituting 5% to 13% of all osteosarcoma is a locally aggressive malignant mesenchymal tumor with high tendency to local recurrence and the ability to produce tumor osteoid.
  • CASE REPORT: The presented case deals with a 60-year-old male patient suffering from a newly occurred polypous mucosal tumor of the right-sided maxillary alveolar ridge bioptically diagnosed as a granulation tissue polyp first.
  • After transmaxillary resection of the tumor and consultation of a bone tumor reference center the final diagnosis of a high-grade chondroblastic osteosarcoma could be made.
  • The recommended radical resection of the tumor was declined by the patient because of the expected cosmetic consequences.
  • After surgical reduction of the rapidly growing sarcoma chemotherapy according to the COOS/EURO-B.O.S.S. protocol was initiated at a stage when computed tomography showed diffuse metastatic disease to the lungs.
  • Chemotherapy could delay the progress of the disease only temporarily.
  • CONCLUSION: In JOS radical surgical resection is the therapy of first choice.
  • For substantiation of the diagnosis and central registration of the cases a bone tumor reference center should be contacted.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Chemotherapy, Adjuvant. Diagnosis, Differential. Disease Progression. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Apr;91(4):445-51 [11312461.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):203-10 [8000997.001]
  • [Cites] Cancer. 1983 Jun 15;51(12):2311-6 [6573939.001]
  • [Cites] J Craniomaxillofac Surg. 1991 Feb;19(2):90-3 [2037699.001]
  • [Cites] Cancer. 1990 Feb 1;65(3):439-45 [2297634.001]
  • [Cites] Arch Otolaryngol. 1977 Aug;103(8):485-8 [267450.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1985 Jul;60(1):56-60 [3862014.001]
  • [Cites] Quintessence Int. 2004 Mar;35(3):228-33 [15119682.001]
  • [Cites] J Oral Maxillofac Surg. 1997 Oct;55(10):1177-81 [9331247.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1991 Jul;117(7):761-6 [1863442.001]
  • [Cites] Laryngoscope. 1997 Jan;107(1):56-61 [9001266.001]
  • [Cites] Am J Surg. 1980 Oct;140(4):572-6 [6932821.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994 Nov;30B(6):374-6 [7719220.001]
  • [Cites] Am J Clin Pathol. 1970 Oct;54(4):625-36 [5273163.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1991 Oct;72(4):444-8 [1923444.001]
  • [Cites] J Maxillofac Surg. 1978 Nov;6(4):273-6 [83344.001]
  • [Cites] Cancer. 1991 Oct 1;68(7):1555-63 [1893357.001]
  • [Cites] Oncogene. 2002 Aug 29;21(38):5975-80 [12185601.001]
  • (PMID = 16947065.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Kutsal A, Tansal S, Okutan H, Tuncer I: Primary malignant mesenchymoma of the heart. Eur J Cardiothorac Surg; 2002 Jan;21(1):124-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant mesenchymoma of the heart.
  • Primary malignant cardiac tumours are uncommon, and cardiac malignant mesenchymoma is extremely rare.
  • A case of primary malignant mesenchymoma in a 41-year-old woman arousing from the left atrial septum, obstructing the mitral orifice by passing through it into the left ventricle is described.
  • The tumour was fully resected, and adjuvant chemotherapy was applied, but the patient had died by tumour recurrence in 8 months.
  • [MeSH-major] Heart Neoplasms / surgery. Mesenchymoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11788281.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Brassens S, Chevalier JM, Leblainvaux M: [A strange case of phlebitis]. Ann Cardiol Angeiol (Paris); 2003 Dec;52(6):375-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Report of a rare case concerning an elderly man (81 years) suffering from a leiomyosarcoma of the leg already metastasized to the lungs, discovered in connection with a suspected thrombophlebitis.
  • This sarcoma developed from the smooth muscle of a leg vessel, probably a vein.
  • Leiomyosarcoma is a malignant mesenchymal tumor of specialized connective tissue, with a strong potential for local proliferation and metastatic spread.
  • The diagnosis suggested by imaging techniques (in particular MRI) is first and foremost immunohistochemical.
  • The treatment is surgical when possible, associated with radiotherapy and chemotherapy as appropriate.
  • The prognosis is especially poor when the diagnosis is made at the metastatic stage.
  • [MeSH-major] Leiomyosarcoma / diagnosis. Popliteal Vein / pathology. Thrombophlebitis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14752921.001).
  • [ISSN] 0003-3928
  • [Journal-full-title] Annales de cardiologie et d'angéiologie
  • [ISO-abbreviation] Ann Cardiol Angeiol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


16. Nestler G, Halloul Z, Evert M, Dombrowski F, Lippert H, Meyer F: Myogenous sarcoma of the gallbladder with a hemangiopericytomatous pattern. J Hepatobiliary Pancreat Surg; 2007;14(2):197-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myogenous sarcoma of the gallbladder with a hemangiopericytomatous pattern.
  • Primary sarcoma of the gallbladder is a very rare neoplasm, and there are few instances of its diagnostic and therapeutic management.
  • We describe a 66-year-old male patient with a sarcoma of the gallbladder.
  • He initially underwent a laparoscopic cholecystectomy, converted to an open procedure.
  • Histology showed a primary sarcoma of the gallbladder (NOS).
  • Histological investigation revealed a malignant mesenchymal tumor lesion, which was classified as a myogenous sarcoma with a hemangiopericytomatous pattern.
  • After an 11-month, uneventful, postoperative course, local tumor recurrence was diagnosed.
  • Palliative chemotherapy was scheduled, but the patient died of advanced tumor recurrence 10 days after this diagnosis.
  • Despite a poor overall prognosis, extensive surgical resection is favored for myogeneous sarcoma of the gallbladder; this procedure is based on precise clarification of the histopathological diagnosis, and can be followed by attempts with radiation of chemotherapy if early diagnosis-finding has failed.
  • This approach allowed, in our patient with this rare neoplasm, a remarkable tumor-free survival of almost 1 year.
  • [MeSH-major] Gallbladder Neoplasms / pathology. Sarcoma / pathology
  • [MeSH-minor] Aged. Cholecystectomy. Humans. Immunohistochemistry. Lymph Node Excision. Male. Reoperation. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17384914.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Oppenheimer O, Athanasian E, Meyers P, Antonescu CR, Gorlick R: Malignant ectomesenchymoma in the wrist of a child: case report and review of the literature. Int J Surg Pathol; 2005 Jan;13(1):113-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant ectomesenchymoma in the wrist of a child: case report and review of the literature.
  • Malignant ectomesenchymomas, rare and potentially aggressive tumors, occur in children and exhibit mesenchymal and neuroectodermal components.
  • This report describes the first patient diagnosed with a malignant ectomesenchymoma of the hand.
  • The patient was a 17-month-old male who developed a hypothenar mass on his left hand that was surgically excised.
  • After 3 courses of chemotherapy the patient had a wide reexcision with no residual tumor.
  • The patient is 4 years from diagnosis, without evidence of disease.
  • [MeSH-major] Mesenchymoma / pathology. Soft Tissue Neoplasms / pathology. Wrist
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Infant. Male. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for ectomesenchymoma .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735865.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 17
  •  go-up   go-down


18. Floris G, Debiec-Rychter M, Wozniak A, Magrini E, Manfioletti G, De Wever I, Tallini G, Sciot R: Malignant ectomesenchymoma: genetic profile reflects rhabdomyosarcomatous differentiation. Diagn Mol Pathol; 2007 Dec;16(4):243-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant ectomesenchymoma: genetic profile reflects rhabdomyosarcomatous differentiation.
  • Malignant ectomesenchymoma (MEM) represents a heterogeneous group of tumors, most likely originating from pluripotent primitive neural crest cells.
  • Retrospective review of the incision biopsy showed the presence of a few ganglion cells in an otherwise classic embryonal rhabdomyosarcoma (RMS), whereas in the resection specimen after chemotherapy the combined RMS and ganglioneuroma components were very obvious.
  • Cytogenetic analysis of the residual lesion showed an abnormal karyotype, 49, XY, +2, -6, +11, +20, +mar, with a hyperploidy in a subset of cells.
  • By fluorescence in situ hybridization analysis, the marker chromosome was identified as originating from chromosome 6, and the tumor cells were negative for PAX3/PAX7 disrupting translocations specific for alveolar RMS.
  • The genomic profiles of both specimens were basically the same including the presence of 2 distinctive chromosome 6p21.32-p21.2 and 6p11.2 amplification regions in the primary tumor, which vanished in the postchemotherapy specimen.
  • The pretreatment biopsy exhibited strong expression of HMGA1 and HMGA2 proteins in immunohistochemistry, with the shift toward the loss of expression of both genes in the posttreatment tumoral tissue.
  • This finding supports the oncogenic properties of the HMGA family of proteins and their role in the process of malignant transformation.
  • [MeSH-major] Gene Expression Profiling. Genital Neoplasms, Male / diagnosis. Mesenchymoma / diagnosis. Rhabdomyosarcoma, Embryonal / diagnosis. Scrotum
  • [MeSH-minor] Chromosome Aberrations. Diagnosis, Differential. HMGA1a Protein / analysis. HMGA2 Protein / analysis. Humans. Infant. Male. Oligonucleotide Array Sequence Analysis. PAX7 Transcription Factor / analysis. Paired Box Transcription Factors / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043289.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HMGA2 Protein; 0 / PAX3 protein, human; 0 / PAX7 Transcription Factor; 0 / PAX7 protein, human; 0 / Paired Box Transcription Factors; 124544-67-8 / HMGA1a Protein
  •  go-up   go-down


19. Ekinci S, Karnak I, Tanyel FC, Senocak ME, Kutluk T, Büyükpamukçu M, Büyükpamukçu N: Hepatic lobectomies in children: experience of a center in the light of changing management of malignant liver tumors. Pediatr Surg Int; 2006 Mar;22(3):228-32
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic lobectomies in children: experience of a center in the light of changing management of malignant liver tumors.
  • Hepatic resection is the main treatment modality for hepatic tumors in childhood.
  • The aim of this study is to report our experience in hepatic lobectomy, which is relatively rare procedure in childhood.
  • Age, gender, diagnosis, physical examination findings, results of preoperative laboratory investigations, radiological examination, resectability criteria, preoperative biopsies, chemotherapies, radiotherapies, postoperative pathological results, incisions, operation technique, intraoperative transfusions, drains used, antibiotic prophylaxes, and intraoperative and postoperative complications were evaluated for all patients.
  • Out of 25 patients with hepatic tumor seven patients with hepatoblastoma and four patients with hepatocellular carcinoma were given 5.7 +/- 0.3 cycles of chemotherapy before the operation.
  • Pathological examination of resected tumors revealed hepatoblastoma (n=11), mesenchymal hamartoma (n = 5), hepatocellular carcinoma (n = 4), hemangioendothelioma (n=1), malignant mesenchymal tumor (n = 1), hemangioma (n = 1), cyst adenoma (n = 1), and metastasis of cellular mesoblastic nephroma (n = 1).
  • [MeSH-minor] Child, Preschool. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Infant. Magnetic Resonance Imaging. Male. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pediatr Surg Int. 2006 Aug;22(8):695
  • [Cites] Eur Urol. 1997;32(2):194-7 [9286653.001]
  • [Cites] J Pediatr Surg. 1991 Nov;26(11):1326-30 [1812268.001]
  • [Cites] Br J Surg. 1995 Mar;82(3):386-91 [7796018.001]
  • [Cites] Ann Thorac Surg. 1991 May;51(5):717-21; discussion 721-2 [1850976.001]
  • [Cites] J Pediatr Surg. 1984 Oct;19(5):523-6 [6094781.001]
  • [Cites] Surg Gynecol Obstet. 1957 Sep;105(3):310-8 [13467662.001]
  • [Cites] J Surg Res. 1996 Feb 15;61(1):183-9 [8769964.001]
  • [Cites] Surgery. 1998 Apr;123(4):407-14 [9551066.001]
  • [Cites] Hum Pathol. 1983 Jun;14(6):512-37 [6303939.001]
  • [Cites] Chirurgie. 1986;112(5):337-42 [3608701.001]
  • [Cites] World J Surg. 1982 Jan;6(1):3-9 [7090393.001]
  • [Cites] J Pediatr Surg. 2000 Oct;35(10 ):1459-61 [11051151.001]
  • [Cites] World J Surg. 1997 Mar-Apr;21(3):330-42 [9015180.001]
  • [Cites] J Pediatr Surg. 1992 Aug;27(8):1080-3; discussion 1083-4 [1328586.001]
  • [Cites] AJR Am J Roentgenol. 1993 Sep;161(3):572-3 [8352107.001]
  • [Cites] J Pediatr Surg. 1992 Jul;27(7):912-5 [1322458.001]
  • [Cites] J Pediatr Surg. 2001 May;36(5):755-9 [11329582.001]
  • (PMID = 16395609.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


20. Stewart RJ, Martelli H, Oberlin O, Rey A, Bouvet N, Spicer RD, Godzinski J, Stevens MC, International Society of Pediatric Oncology: Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology. J Clin Oncol; 2003 Mar 1;21(5):793-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology.
  • PURPOSE: To report the results of the Malignant Mesenchymal Tumors studies (MMT 84 and 89) of the International Society of Pediatric Oncology (SIOP) in males with nonmetastatic paratesticular rhabdomyosarcoma.
  • Disease was staged according to the SIOP tumor-node-metastasis staging system.
  • Treatment was stratified by stage.
  • In the MMT 89 study, males with completely resected tumors at diagnosis received less chemotherapy (vincristine and dactinomycin) than patients in the MMT 84 study (ifosfamide, vincristine, and dactinomycin).
  • RESULTS: Median age at diagnosis was 65 months.
  • Thirty-one tumors were larger than 5 cm, and 13 males were older than 10 years with a tumor larger than 5 cm.
  • OS and EFS were significantly worse for males with tumors greater than 5 cm and for males older than 10 years at diagnosis.
  • CONCLUSION: Males with paratesticular RMS have an excellent prognosis except for a selected group of patients older than 10 years or with tumor greater than 5 cm.
  • Intensified chemotherapy incorporating alkylating agents for this subgroup may be preferred to the use of systematic lymphadenectomy to improve survival while minimizing the burden of therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dactinomycin / therapeutic use. Ifosfamide / therapeutic use. Mesenchymoma / drug therapy. Rhabdomyosarcoma / drug therapy. Testicular Neoplasms / drug therapy. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Humans. Infant. Lymph Node Excision. Male. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Salvage Therapy. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12610176.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; UM20QQM95Y / Ifosfamide; IVA protocol; SIOP protocol
  •  go-up   go-down


21. Weiss E, Albrecht CF, Herms J, Behnke-Mursch J, Pekrun A, Brockmann K, Hess CF: Malignant ectomesenchymoma of the cerebrum. Case report and discussion of therapeutic options. Eur J Pediatr; 2005 Jun;164(6):345-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for ectomesenchymoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant ectomesenchymoma of the cerebrum. Case report and discussion of therapeutic options.
  • Malignant ectomesenchymoma is a rare tumour that contains both ectodermal and mesenchymal elements.
  • Only three patients with a manifestation in the cerebrum and clinicopathological data have been reported until now.
  • We present a patient with an intracerebral ectomesenchymoma, review the literature and discuss currently available therapeutic options.
  • For the mesenchymal part of the tumour she subsequently underwent multidrug chemotherapy followed by radiation therapy.
  • Considering the neuroectodermal element of the tumour, radiotherapy was applied to the craniospinal axis with a local boost.
  • Therapy was tolerated well without any severe side effects.
  • Six years from diagnosis, the patient is alive without a tumour relapse.
  • CONCLUSION: Due to the sparcity of reported cases with malignant ectomesenchymoma, the role of adjuvant therapy is unclear.
  • Multimodal therapy may be able to improve outcome.
  • [MeSH-major] Brain Neoplasms. Cerebral Cortex. Mesenchymoma. Neuroectodermal Tumors
  • [MeSH-minor] Child. Combined Modality Therapy. Female. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 1997 Sep;32(9):1351-5 [9314261.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1687-96 [7602359.001]
  • [Cites] J Neurosurg. 1971 Mar;34(3):417-22 [5313338.001]
  • [Cites] Pediatr Radiol. 1997 Aug;27(8):682-4 [9252435.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1977 Sep-Oct;2(9-10):1007-16 [271145.001]
  • [Cites] Cancer. 1987 Jan 1;59(1):147-55 [3791141.001]
  • [Cites] J Neurosurg. 1946 Nov;3(6):511-32 [20279147.001]
  • [Cites] Pediatr Neurosurg. 1999 Jun;30(6):320-30 [10494059.001]
  • [Cites] Pediatr Radiol. 2001 Mar;31(3):169-72 [11297080.001]
  • [Cites] J Neurosurg. 1994 Nov;81(5):690-8 [7931615.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Aug 1;36(1):29-35 [8823256.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):265-74 [2394606.001]
  • [Cites] Cancer. 1987 May 15;59(10):1791-802 [2950992.001]
  • [Cites] Histopathology. 1991 May;18(5):395-402 [1715839.001]
  • [Cites] Semin Pediatr Surg. 1994 Aug;3(3):203-6 [7987636.001]
  • (PMID = 15747131.001).
  • [ISSN] 0340-6199
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 17
  •  go-up   go-down


22. Paramelle O, Croué A, Dupré F, Rialland X, Saint-André JP: [Pelvic malignant ectomesenchymoma: a case report]. Ann Pathol; 2001 Aug;21(4):344-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pelvic malignant ectomesenchymoma: a case report].
  • [Transliterated title] Ectomésenchymome malin pelvien. A propos d'un cas.
  • We report the case of a 19 month old boy referred to our institution because of a pelvic tumor initially identified as an embryonal rhabdomyosarcoma and treated with surgery and chemotherapy.
  • Eight years after the initial surgery, a local tumor recurrence with bone metastasis was found.
  • This double differentiation was retrospectively found in the initial tumor, then allowing the diagnosis of malignant ectomesenchymoma also called gangliorhabdomyosarcoma.
  • This rare tumor, occurring mainly during childhood, is composed of neuroblasts and / or ganglion cells and of malignant mesenchymal cells (usually rhabdomyosarcomatous cells).
  • [MeSH-major] Mesenchymoma / pathology. Pelvic Neoplasms / pathology. Rhabdomyosarcoma / pathology
  • [MeSH-minor] Bone Neoplasms / secondary. Cell Differentiation. Diagnosis, Differential. Fatal Outcome. Femoral Neoplasms / secondary. Ganglia / pathology. Humans. Immunohistochemistry. Infant. Male. Neoplasm Recurrence, Local. Neurons / pathology. Rhabdomyosarcoma, Embryonal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11685134.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


23. Benateau H, Rigau V, Martin JP, Labbé D, Compère JF: [Diagnostic difficulties of chondrosarcoma of the jaw. Apropos of a case and review of the literature]. Rev Stomatol Chir Maxillofac; 2000 Apr;101(2):80-5
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Difficultés diagnostiques du chondrosarcome des maxillaires. A propos d'un cas et revue de la littérature.
  • Chondrosarcoma is an uncommon malignant mesenchymal tumor characterized by the production of cartilaginous tissue and the absence of production of bone tissue.
  • The clinical and radiographic findings are similar to those seen in other tumors of the jaw, often delaying diagnosis and treatment and subsequently jeopardizing prognosis.
  • In the literature, the mean delay from first clinical signs to diagnosis is about 8 months.
  • As in all tumoral diseases, pathology confirms the diagnosis.
  • We report a case of chondrosarcoma of the maxillary bone and review the literature, focusing on the difficulty in establishing the diagnosis, even at the pathology examination.
  • We propose wide surgical excision, which, in agreement with other reports in the literature, is the only therapeutic possibility.
  • Radiotherapy and chemotherapy may be useful in certain cases.
  • [MeSH-major] Chondrosarcoma / diagnosis. Mandibular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Bone and Bones / pathology. Cartilage / pathology. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Mandible / surgery. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10859759.001).
  • [ISSN] 0035-1768
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] FRANCE
  • [Number-of-references] 40
  •  go-up   go-down


24. Paikos P, Papathanassiou M, Stefanaki K, Fotopoulou M, Grigorios S, Tzortzatou F: Malignant ectomesenchymoma of the orbit in a child: Case report and review of the literature. Surv Ophthalmol; 2002 Jul-Aug;47(4):368-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant ectomesenchymoma of the orbit in a child: Case report and review of the literature.
  • Malignant ectomesenchymoma is a rare soft tissue tumor of childhood composed of both mesenchymal and neuroectodermal elements.
  • The clinical picture of the tumor, radiological findings, and its histopathologic and immunohistochemical characteristics are described.
  • The patient was successfully treated with combined surgical resection and chemotherapy.
  • All the other reported cases of malignant ectomesenchymoma with various sites of origin are also reviewed.
  • [MeSH-major] Mesenchymoma / pathology. Orbital Neoplasms / pathology
  • [MeSH-minor] Child. Combined Modality Therapy. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12161212.001).
  • [ISSN] 0039-6257
  • [Journal-full-title] Survey of ophthalmology
  • [ISO-abbreviation] Surv Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


25. Müller HL, Marx A, Trusen M, Schneider P, Kühl J: Disseminated malignant ectomesenchymoma (MEM): case report and review of the literature. Pediatr Hematol Oncol; 2002 Jan-Feb;19(1):9-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated malignant ectomesenchymoma (MEM): case report and review of the literature.
  • Malignant ectomesenchymoma (MEM) is a rare soft tissue tumor believed to arise from a pluripotent migratory neural crest cell and composed fo both a mesenchymal element and a neuroectodermal element.
  • The authors report the case of an 11-month-old male who presented with a local abdominal MEM and systemic metastases into lungs, liver, bones, and bone marrow.
  • The tumor consisted of a neuroblastoma component and a mesenchymal component with sarcomatous features.
  • Diagnosis and therapy were complicated by the histological heterogeneity of the tumor, which also influenced the clinical appearance and course in this case.
  • A literature search revealed 15 other evaluated cases that arose in soft tissue and had adequate clinicopathologic data.
  • Complete surgical resection was the mainstay of treatment, and chemotherapy also appeared to be important.
  • In patients with disseminated MEM, new therapeutic approaches such as high-dose chemotherapy followed by stem cell rescue should be considered, similar to the current strategy in patients with stage VI neuroblastoma or soft tissue sarcoma.
  • [MeSH-major] Abdominal Neoplasms / pathology. Mesenchymoma / secondary
  • [MeSH-minor] 3-Iodobenzylguanidine. Bone Marrow Neoplasms / radionuclide imaging. Bone Marrow Neoplasms / secondary. Bone Marrow Neoplasms / therapy. Fatal Outcome. Humans. Infant. Magnetic Resonance Imaging. Male. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11787870.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 35MRW7B4AD / 3-Iodobenzylguanidine
  • [Number-of-references] 13
  •  go-up   go-down


26. de Bouyn-Icher C, Minard-Colin V, Isapof A, Khuong Quang DA, Redon I, Hartmann O: [Malignant solid tumors in neonates: a study of 71 cases]. Arch Pediatr; 2006 Dec;13(12):1486-94
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant solid tumors in neonates: a study of 71 cases].
  • [Transliterated title] Tumeurs solides malignes néonatales: à propos de 71 cas.
  • Malignant neonatal tumors are rare and comprise 2% of childhood malignancies.
  • Clinical features, histologic types, prognosis were very different from those seen in older children, facing oncologists with diagnostic, therapeutic and ethical problems.
  • PATIENTS AND METHODS: In a retrospective study from January 1987 to January 2004, we reviewed the management of neonates treated at the Institute Gustave Roussy for a malignant solid tumor for whom symptoms started in the first month of life.
  • RESULTS: Seventy-one neonates were treated, comprising 1,2% of the overall patients treated during the same period of time.
  • Of these 71 patients, 42 (59%) presented with neuroblastomas, 12 (17%) with mesenchymal tumors, 6(8%) with cerebral tumors and 11 with various other types of tumors.
  • Thirty-eight neonates received chemotherapy, administered at a 30 to 50% reduced dose.
  • Hematologic toxicities and infections were the main therapeutic complications.
  • There has been no therapy-related mortality.
  • CONCLUSIONS: Neonatal malignant solid tumors, except for cerebral tumors, have a good prognosis.
  • The young age of patients resulted in problems of treatment tolerance.
  • The therapeutic regimen should take into account the risk of acute iatrogenic toxicity and long term sequelae.
  • Surgery remains the treatment of choice but chemotherapy, with dose reduction, managed by expert teams, is essential and safer in a lot of case.
  • [MeSH-major] Brain Neoplasms / epidemiology. Mesenchymoma / epidemiology. Neuroblastoma / epidemiology
  • [MeSH-minor] Adolescent. Age Factors. Antineoplastic Agents / therapeutic use. Brain / pathology. Child. Child, Preschool. Female. France / epidemiology. Humans. Incidence. Infant. Infant, Newborn. Male. Neoplasm Staging. Prenatal Diagnosis. Prognosis. Radiotherapy Dosage. Retrospective Studies. Risk Factors. Sex Factors. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17137765.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


27. Machaladze ZO, Davydov MI, Polotskiĭ BE, Karseladze AI, Savelov NA: [Surgery for mesenchymal tumours of the mediastinum]. Khirurgiia (Mosk); 2008;(4):43-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgery for mesenchymal tumours of the mediastinum].
  • Results of treatment of 52 patients with mesenchymal tumours of the mediastinum.
  • Computer tomography and MRT are the most informative diagnostic techniques.
  • Among 52 patients with mesenchymal tumours of the mediastinum, 40 patients were treated surgically and 12 patients got conservative treatment.
  • Chemotherapy and radiotherapy were carried out in 7 patients in pre- and postoperative periods.
  • Radical surgical treatment was carried out in 21 patients with benign tumors.
  • Among 19 patients with malignant tumors, 42% of patients got radical surgical treatment, and 58 % of patients got palliative therapy in combination with chemotherapy.
  • Benign tumors have a favorable prognosis after surgical treatment.
  • Major factors of the prognosis of surgical treatment are dissemination and the histologic form of a tumor as well as type of surgical intervention.
  • [MeSH-major] Mediastinal Neoplasms / surgery. Mediastinoscopy / methods. Mesenchymoma / surgery. Thoracic Surgery, Video-Assisted / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18454108.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


28. Utkan G, Buyukcelik A, Demir O, Sanli H, Pamir A: Post-transfusion acute graft versus host disease in a 17-year-old girl with a malignant mesenchymal tumor--report of a case. Acta Med Austriaca; 2003;30(5):138-41
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-transfusion acute graft versus host disease in a 17-year-old girl with a malignant mesenchymal tumor--report of a case.
  • There is no standard treatment for PT-GVHD and irradiation of blood and its components before transfusion is broadly accepted for the prevention of PT-GVHD.
  • In this report we present a case (a 17-year-old female) of PT GVHD, who died in spite of the use of all available therapeutic options.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Erythrocyte Transfusion / adverse effects. Graft vs Host Disease / diagnosis. Mesenchymoma / drug therapy

  • Genetic Alliance. consumer health - Malignant mesenchymal tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15055161.001).
  • [ISSN] 0303-8173
  • [Journal-full-title] Acta medica Austriaca
  • [ISO-abbreviation] Acta Med. Austriaca
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


29. Högenauer C, Langner C, Lipp RW, Höfler G, Krejs GJ, Hinterleitner TA: Complete remission of a metastatic gastrointestinal stromal tumour with the tyrosine kinase inhibitor imatinib (STI 571): effect of low dosage in an advanced tumour with exon 11 mutation. Eur J Gastroenterol Hepatol; 2003 Mar;15(3):323-7
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a 51-year-old man with an advanced malignant metastatic gastrointestinal stromal tumour, who showed a complete response after 5 months of treatment with imatinib at a dose of 400 mg per day.
  • An early treatment response was demonstrated in an 18fluorodeoxyglucose positron emission tomography scan after 1 month of therapy.
  • Complete remission was documented histologically by negative serial biopsies of residual tumour nodes after 5 months of therapy.
  • A 21 bp, exon 11, in-frame mutation of the c-kit gene was found by DNA sequence analysis of tumour tissue.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Neoplasms / drug therapy. Mesenchymoma / drug therapy. Mesenchymoma / secondary. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use
  • [MeSH-minor] Benzamides. Enzyme Inhibitors / therapeutic use. Humans. Imatinib Mesylate. Male. Middle Aged. Mutation. Remission Induction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12610329.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Enzyme Inhibitors; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down






Advertisement